Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis strengthens in biotechnology

Sanofi-aventis has invested almost €200m to convert its pharmaceutical production site at Vitry-sur-Seine in France to produce monoclonal antibodies

As part of its move to enhance its presence in the biotechnology field, sanofi-aventis has invested almost €200m to convert its pharmaceutical production site at Vitry-sur-Seine in France to produce monoclonal antibodies from 2012.

The factory will be the site for 'Biolaunch', a project that will promote the first cell culture biotechnology platform of the group. 

"Monoclonal antibodies will open the way to a new generation of better targeted and more effective treatments with fewer side effects," declared chief executive officer, Chris Viehbacher. "This project, which gathers and mobilises the best expertise both inside and outside the company, is an illustration of the ongoing transforming programme within sanofi-aventis."

The change of use is part of a long-term approach to develop sanofi-aventis' investments in the biotechnological sector, augmenting the group's current production of vaccines, insulins and heparins.  

This project is a core part of the conversion plan for the site, which aims to turn it into a comprehensive biotechnology platform for research, development and production. Furthermore, the facility will be made available to other companies to use for development or production, enabling sanofi-aventis to benefit from partnerships that could result in new products.

The Biolaunch project is linked with a major training programme in new biotech business activities, which comprises modules in both theory and practice.

6th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics